NPI registry status
Active
2026 NPPES data Medical Oncology Physician NPI 1528257383 M.D.
Verify on CMS → Gary Erwin, M.D.
Medical Oncology Physician in Houston, Texas.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 3,792 in Medical Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
245
Medicare Part D claims · 45 beneficiaries · Medical Oncology Physician avg: 689
Generic prescribing
76%
generic claims · 24% brand-name · higher generic rates reduce patient out-of-pocket costs
Source: CMS Medicare Part D Prescriber Public Use File, 2023
Compiled from official public sources by the PlainDoctor editorial team.
What the federal data shows
Gary Erwin, M.D. filed 245 Medicare Part D claims in 2023 as a Medical Oncology Physician in Houston, Texas, prescribing 76% generic.
- 245
- Part D claims, 2023
- 76%
- generic prescribing
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Gary Erwin, M.D.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023, across all CMS prescribers nationally
245 49th percentile higher than 49% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
◑
Board-eligible specialty (heuristic, not verified)
Gary Erwin, M.D. practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Gary Erwin, M.D.?
Quality data not reportedPrimary specialty
Medical Oncology Physician
Medicare Part D claims
245 64% vs specialty avg
Specialty distribution in Texas
How Medical Oncology Physician compares to other specialties among Texas providers
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Medical Oncology Physician. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Gary Erwin, M.D. appears in the CMS NPPES registry as a Medical Oncology Physician provider holding M.D. credentials at 5206 FM 1960 RD W STE 104, Houston, TX, 77069, with a listed phone of (281) 587-2316. NPI 1528257383 was issued on 10/17/2007.
Medicare Part D records for calendar year 2023 show 245 prescription claims written by this provider, covering 45 Medicare beneficiaries and totaling roughly $29K in drug spend, split 24% brand-name and 76% generic by claim count.
Medical Oncology Physician is a narrow specialty nationwide, with 3,792 enrolled providers across 53 states and an average of 689 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1528257383 |
|---|---|
| Specialty | Medical Oncology Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 10/17/2007 |
License & disciplinary context - Texas TMB 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 - they are NOT specific to Gary Erwin, M.D.. To verify Gary Erwin, M.D.'s current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
344
Total board actions, Texas 2023
Across 334 cases
4.47
Actions per 1,000 licensees
Texas statewide rate
probation
Most common action type
94 cases
TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Typical
Gary Erwin, M.D. - brand share 24.0%
Medical Oncology Physician average
24% brand-name claims vs 76% generic, on 245 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
245
Total Claims
$29K
Total Drug Cost
45
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 385
- Total Day Supply
- 10,949
- Brand vs Generic
- 24% brand / 76% generic
- Brand Drug Cost
- $24K
- Generic Drug Cost
- $4K
Patient Demographics
- Average Patient Age
- 83.3 years
- Avg HCC Risk Score
- 3.33
- Gender Split
- 60% female / 40% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Gary Erwin, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Eliquis
Eliquis
17 claims
- Montelukast Sodium
Montelukast Sodium
16 claims
- Amlodipine Besylate
Amlodipine Besylate
11 claims
| Drug | Claims |
|---|---|
| Eliquis Apixaban | 17 |
| Montelukast Sodium | 16 |
| Amlodipine Besylate | 11 |
| Lantus Solostar "Insulin Glargine | N/A |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Medical Oncology Physician Overview
How Gary Erwin, M.D. fits within the Medical Oncology Physician landscape nationally.
3,792
Medical Oncology Physician Providers in US
53
States with Medical Oncology Physician
689
Avg Claims per Provider
Gary Erwin, M.D.'s 245 claims are below the specialty average of 689.
Nearby Medical Oncology Physician Providers in Texas
Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as Erwin.
Dr. Chinemerem Abanonu
MD
Katy, TX
Dr. James Abbruzzese
M.D.
Houston, TX
Dr. Seyed Abedi
M.D.,PH.D.
Cedar Park, TX
Dr. Sausan Abouharb
M.D
Houston, TX
Dr. Fadi Abu-Shahin
MD
Houston, TX
Compare Medical Oncology Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the Texas medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Medical Oncology Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
How to Find a Doctor
Step-by-step guide to choosing a provider
Verify Credentials
Check NPI, board certification & license status
Medical Specialties Explained
Who treats what and how specialties differ
Understanding Medicare Claims Data
What prescribing data reveals about a provider
In-Network vs Out-of-Network
How insurance networks affect your costs
Telehealth Guide
Virtual care options and coverage in 2026
Explore Texas
Frequently Asked Questions
What is Gary Erwin, M.D.'s specialty? ▼
Gary Erwin, M.D. specializes in Medical Oncology Physician and practices in Houston, Texas. Credentials: M.D..
How much does Gary Erwin, M.D. prescribe under Medicare Part D? ▼
In 2023, Gary Erwin, M.D. wrote 245 Medicare Part D claims totaling $29K in drug costs for 45 beneficiaries.
Where is Gary Erwin, M.D. located? ▼
Gary Erwin, M.D. is located at 5206 FM 1960 RD W STE 104, Houston, TX, 77069. Phone: (281) 587-2316.
What is Gary Erwin, M.D.'s NPI number? ▼
Gary Erwin, M.D.'s National Provider Identifier (NPI) is 1528257383, issued on 10/17/2007.
Does Gary Erwin, M.D. prescribe more brand-name or generic drugs? ▼
Gary Erwin, M.D.'s prescribing is 24% brand-name and 76% generic drugs by claim count, with $24K in brand drug costs.
How many Medical Oncology Physician providers are there in the US? ▼
There are 3,792 Medical Oncology Physician providers across 53 states in the US. The average Medical Oncology Physician provider writes 689 Medicare Part D claims per year.
What drugs does Gary Erwin, M.D. prescribe most often? ▼
Based on 2023 Medicare Part D data, Gary Erwin, M.D.'s most frequently prescribed drugs include Eliquis, Montelukast Sodium, Amlodipine Besylate. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Gary Erwin, M.D. accept Medicare? ▼
Gary Erwin, M.D. appears in CMS Medicare data with 245 Part D claims and 45 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Gary Erwin, M.D.'s credentials? ▼
Gary Erwin, M.D.'s NPI is 1528257383 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Compiled from official public sources by the PlainDoctor editorial team.